These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 36705879)

  • 41. EZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma.
    Xu T; Dai J; Tang L; Yang L; Si L; Sheng X; Cui C; Chi Z; Kong Y; Guo J
    J Invest Dermatol; 2022 Apr; 142(4):1158-1170.e8. PubMed ID: 34571002
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure-Activity relationship study of benzothiophene oxobutanoic acid analogues leading to novel stimulator of interferon gene (STING) agonists.
    Shen A; Li X; Zhang Y; Ma J; Xiao R; Wang X; Song Z; Liu Z; Geng M; Zhang A; Xie Z; Ding C
    Eur J Med Chem; 2022 Nov; 241():114627. PubMed ID: 35963129
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cocktail strategy based on a dual function nanoparticle and immune activator for effective tumor suppressive.
    Li Q; Chen Q; Yang X; Zhang Y; Lv L; Zhang Z; Zeng S; Lv J; Liu S; Fu B
    J Nanobiotechnology; 2022 Feb; 20(1):84. PubMed ID: 35177088
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Agonist of stimulator of interferon genes as antitumor agents: a patent review (2008-2020).
    Chen NN; Zhang H; You QD; Xu XL
    Expert Opin Ther Pat; 2021 Jun; 31(6):563-584. PubMed ID: 33459063
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systemic Delivery of a STING Agonist-Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis.
    Go EJ; Yang H; Park W; Lee SJ; Han JH; Kong SJ; Lee WS; Han DK; Chon HJ; Kim C
    Small; 2023 Oct; 19(43):e2300544. PubMed ID: 37381624
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Brief report: STING expressed in tumor and non-tumor compartments has distinct roles in regulating anti-tumor immunity.
    Kim JC; Liu X; Fitzgerald K; Eng JS; Orf J; O'Brien SA; Belmontes B; Casbon AJ; Novitskiy SV; Tarbell KV; DeVoss J; Egen JG
    Cancer Immunol Immunother; 2023 May; 72(5):1327-1335. PubMed ID: 36394642
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Delivery of STING agonists for cancer immunotherapy.
    Wang J; Meng F; Yeo Y
    Curr Opin Biotechnol; 2024 Jun; 87():103105. PubMed ID: 38461748
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy.
    Wu JJ; Zhao L; Hu HG; Li WH; Li YM
    Med Res Rev; 2020 May; 40(3):1117-1141. PubMed ID: 31793026
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer.
    Lombardo KA; Obradovic A; Singh AK; Liu JL; Joice G; Kates M; Bishai W; McConkey D; Chaux A; Eich ML; Rezaei MK; Netto GJ; Drake CG; Tran P; Matoso A; Bivalacqua TJ
    J Pathol; 2022 Feb; 256(2):223-234. PubMed ID: 34731491
    [TBL] [Abstract][Full Text] [Related]  

  • 50. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
    Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
    J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The stimulator of interferon genes (STING) agonists for treating acute myeloid leukemia (AML): current knowledge and future outlook.
    Song X; Peng Y; Wang X; Chen Q; Lan X; Shi F
    Clin Transl Oncol; 2023 Jun; 25(6):1545-1553. PubMed ID: 36587109
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of small molecule inhibitors/agonists targeting STING for disease.
    Liu K; Lan Y; Li X; Li M; Cui L; Luo H; Luo L
    Biomed Pharmacother; 2020 Dec; 132():110945. PubMed ID: 33254439
    [TBL] [Abstract][Full Text] [Related]  

  • 53. STING-induced regulatory B cells compromise NK function in cancer immunity.
    Li S; Mirlekar B; Johnson BM; Brickey WJ; Wrobel JA; Yang N; Song D; Entwistle S; Tan X; Deng M; Cui Y; Li W; Vincent BG; Gale M; Pylayeva-Gupta Y; Ting JP
    Nature; 2022 Oct; 610(7931):373-380. PubMed ID: 36198789
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The cGAS/STING Pathway: A Novel Target for Cancer Therapy.
    Gan Y; Li X; Han S; Liang Q; Ma X; Rong P; Wang W; Li W
    Front Immunol; 2021; 12():795401. PubMed ID: 35046953
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Spatiotemporal release of non-nucleotide STING agonist and AKT inhibitor from implantable 3D-printed scaffold for amplified cancer immunotherapy.
    Wang H; Liu Z; Fang Y; Luo X; Zheng C; Xu Y; Zhou X; Yuan Q; Lv S; Ma L; Lao YH; Tao Y; Li M
    Biomaterials; 2024 Dec; 311():122645. PubMed ID: 38850717
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nanodelivery of cGAS-STING activators for tumor immunotherapy.
    Guo J; Huang L
    Trends Pharmacol Sci; 2022 Nov; 43(11):957-972. PubMed ID: 36089410
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers.
    Yi M; Niu M; Zhang J; Li S; Zhu S; Yan Y; Li N; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2021 Sep; 14(1):146. PubMed ID: 34526097
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways.
    Li K; Qu S; Chen X; Wu Q; Shi M
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216575
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
    Liu C; Wang X; Qin W; Tu J; Li C; Zhao W; Ma L; Liu B; Qiu H; Yuan X
    Cancer Commun (Lond); 2023 Apr; 43(4):435-454. PubMed ID: 36855844
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies.
    Carideo Cunniff E; Sato Y; Mai D; Appleman VA; Iwasaki S; Kolev V; Matsuda A; Shi J; Mochizuki M; Yoshikawa M; Huang J; Shen L; Haridas S; Shinde V; Gemski C; Roberts ER; Ghasemi O; Bazzazi H; Menon S; Traore T; Shi P; Thelen TD; Conlon J; Abu-Yousif AO; Arendt C; Shaw MH; Okaniwa M
    Cancer Res Commun; 2022 Jun; 2(6):489-502. PubMed ID: 36923556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.